Impel NeuroPharma announced the last patient has been enrolled in "STOP-301" (Safety and Tolerability of POD-DHE), the Company's pivotal open-label Phase 3, multi-use, long-term safety and tolerability of INP104 for the treatment of acute migraine.
Novartis announced today results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of Entresto (sacubitril/valsartan) in patients with heart failure with reduced ejection fraction (HFrEF).
VALBIOTIS has announced additional positive results from its Phase IIA clinical study of VALEDIA on four parameters which were among the secondary endpoints of the study: blood triglyceride levels, Fatty Liver Index, (fat accumulation in the liver), blood LDL cholesterol levels, and arterial hypertension.
Roche’s one-dose Xofluza (baloxavir marboxil) has achieved primary endpoint in phase III MINISTONE-2 study of children with flu.
Novartis said that its human anti-CD20 monoclonal antibody ofatumumab (OMB157) showed superiority over Aubagio (teriflunomide) in two phase 3 trials in patients with relapsing forms of multiple sclerosis (RMS).
AstraZeneca’s new medicine anifrolumab has achieved primary endpoint in the phase III Tulip 2 trial of systemic lupus erythematosus (SLE).
VenatoRx Pharmaceuticals today announced that it has initiated enrollment in its Phase 3 trial of cefepime/VNRX-5133 in patients with complicated urinary tract infections (cUTIs).
BeyondSpring, a global biopharmaceutical company focused on the development of innovative cancer therapies, announced the results of its head-to-head clinical trial for Study BPI-2358-105, accepted as an abstract titled, “Quality of Life (QoL) in Advanced NSCLC Patients Treated with Docetaxel and with Either Plinabulin or Pegfilgrastim for the Prevention of Neutropenia.”
ViiV Healthcare said that the injectable two-drug regimen of cabotegravir and rilpivirine succeeded in the ATLAS-2M phase 3 trial in adult patients with HIV-1 by meeting the primary endpoint.
AstraZeneca’s heart failure treatment Farxiga (dapagliflozin) has achieved the primary composite endpoint in the phase III DAPA-HF study.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.